Acute appendicitis, inflammatory appendiceal mass and the risk of a hidden malignant tumor: a systematic review of the literature by unknown
REVIEW Open Access
Acute appendicitis, inflammatory
appendiceal mass and the risk of a hidden
malignant tumor: a systematic review of
the literature
Frederico José Ribeiro Teixeira Jr1, Sérgio Dias do Couto Netto2,3,6*, Eduardo Hiroshi Akaishi4,
Edivaldo Massazo Utiyama5, Carlos Augusto Metidieri Menegozzo7and Marcelo Cristiano Rocha8
Abstract
Introduction: Acute appendicitis is significantly common. Despite the increased use of computed tomography, the
number of perforated cases has been stable in the past three decades. Between 2% and 6% of patients with acute
appendicitis present appendiceal mass, often described as inflammatory phlegmon or abscess. Malignant tumors
are confirmed by pathological analysis in 0.9–1.4% of all appendectomies performed to treat acute appendicitis.
However, recent series demonstrate an elevated incidence of malignancies, ranging from 5.9 to 12%, in patients
with inflammatory appendiceal mass.
Methods: The analysis was based on a systematic review of the literature. The articles were searched in PubMed for
the period from 1987 to 2016. Articles presenting the incidence of the hidden malignancy among patients with
appendiceal inflammatory mass were selected. Variables as age, interval appendectomy rate, the incidence of
neoplasm, time to surgery, minimally invasive assessment, histology, right colectomy rate and morbidity were
analyzed.
Results: A total of 13.244 patients were described as presenting acute appendicitis. Appendiceal tumor is present
in approximately 1% of the appendectomies, while the rate of neoplasm varies from 10 to 29% in patients
presenting appendiceal inflammatory mass. Interval appendectomies, despite been the minority of the procedures,
disregard the higher morbidity associated with right sided colectomies. The review of literature also describes
oncologic, histologic and clinical aspects of patients presenting appendiceal neoplasm, describing the most
frequent histologic subtypes of this illness.
Conclusion: Hidden appendiceal neoplasm in acute appendicitis are rare, fortunately. However, its incidence is
much higher in patients presenting appendiceal inflammatory mass. Hence, interval appendectomy should be
considered in this subgroup of patients.
Keywords: Appendiceal inflammatory mass, Acute appendicits, Appendiceal neoplasms, Appendiceal
neuroendocrine tumors, Pseudomixoma peritonei, Interval appendectomy
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Background
The incidence of appendicitis demanding emergency
surgical treatment is significantly common, with append-
ectomy being used as the standard treatment since 1889
[1]. Only in the US, appendicitis generates about
300,000 annual hospital admissions [2].
Despite the increased use of computed tomography to
evaluate acute abdominal pain and diagnose appendi-
citis, and of laparoscopic appendectomy, the number of
perforated cases has been stable in the past three de-
cades. Between 2 and 6% of patients with acute appendi-
citis present appendiceal mass, often described as
inflammatory phlegmon or abscess [3]. In these cases,
the ideal approach is still controversial, since there are
proposals to an indirect, non-surgical treatment.
When conservative treatments have a positive result at
first, there is often a dilemma whether or not to perform
an interval appendectomy or maintain nonoperative ap-
proach. However, the real disadvantage of the latter is
not having the appendix submitted to histological ana-
lysis. In a meta-analysis and systematic review of 2771
patients diagnosed with inflammatory appendiceal mass
(phlegmon or abscess), Andersson and collaborators
found 31 with malignant tumors [4].
These lesions are detected in 0.9 to 1.4% of the append-
ectomies performed to treat acute appendicitis [5, 6].
Although rare, appendiceal tumors represent about
1% of malignancies of the large intestines. Acute ap-
pendicitis is the initial presentation of primary neo-
plasms of the appendix in more than 50% of the
cases, causing an unpleasant surprise to both the doc-
tor and the patient [7].
It’s reported that 2 to 6% of acute appendicitis cases
consist in inflammatory appendiceal mass [8], and recent
series demonstrate an elevated incidence of malignant
tumors in this organ, between 5.9 and 12% [9, 10].
Methods
The present analysis was made through a Medline
search with the profiles “acute appendicitis AND
(conservative OR interval appendectomy OR mass OR
abscess OR phlegmon)”, and identified references, writ-
ten in English, between 1987 and 2016.
Inclusion criteria for review consisted in searching
articles describing patients older than 18 years-old
treated for acute appendicitis with abdominal abscess
or phlegmon who underwent, or not, interval append-
ectomy, with pathological analysis of the appendix
described.
Based on the title and the abstracts, potential articles
were selected, and the full text was analyzed to identify
original studies that reported results from this treatment.
Variables as age, interval appendectomy rate, the inci-
dence of neoplasm, time to surgery, minimally invasive
assessment, histology, right colectomy rate and morbid-
ity were analyzed.
A review of the literature regarding the main clinical
presentation, oncologic, histopathologic features was
made. In this context, surgical management of appendi-
ceal neoplasms was also highlighted.
Results
A total of 40 initial reports were identified. Four were
excluded because they described interval appendectomy
in children. Seventeen studies were excluded because,
despite being systematic reviews or retrospective case
series, they did not contemplate histologic features from
operated patients. Two other papers were excluded be-
cause they were case reports of only one patient. A total
of nine uncontrolled retrospective series fulfilled the in-
clusion criteria (Fig. 1). A total of 13.244 patients were
described as presenting acute appendicitis.
Eight studies reported the mean ages of patients show-
ing appendicitis [8, 11–17]. Patients presenting with
appendiceal abscess who underwent interval appendec-
tomy were older than those submitted to an upfront ap-
pendectomy. The mean age of patients with usual
appendicitis was 49.7 ± 6 years old (ranging from 41 to
57 years-old). Of those with inflammatory mass, average
age was 52.4 ± 5.9 years old (ranging from 46 to
62 years-old) and 52% of them were male. The majority
of patients was initially managed with immediate ap-
pendectomy or conservative treatment (77,5 and 16% re-
spectively). Only a few patients were subjected to an
interval appendectomy, in a mean of 6.5% in pooled ana-
lysis [8, 11–16, 18]. Six papers reported interval append-
ectomy rates that varied from 1.5% to 28% [8, 16], and
five of them addressed less than 10% of patients been
treated by interval procedure [8, 11, 13, 14]. Even
Tingstedt B. et al [16] states the changes in treatment
choices throughout the decades. Interval appendectomy
was very common before 1995, in up to 46% of the pa-
tients, showing a reduction to 8% after that period.
Laparoscopic appendectomy was less frequent for
interval appendectomy; only two papers [8, 11] were de-
scribing surgical technique. Minimally invasive approach
for appendiceal mass ranged from 54 to 78% compared
to 99%, from the same author, when treating noncompli-
cated appendicitis. The rates of conversion to open pro-
cedures were also higher in appendiceal mass than
usual, varying from 8 to 29% [11, 18].
Four articles [8, 11, 13, 14] described the time to sur-
gery, which ranged from 52 to 78 days, with a mean of
63 ± 11 days.
No patient had appendiceal neoplasm diagnosed pre-
operatively, and overall incidence was extremely low.
From 13.244 patients operated from appendicitis, 206
were submitted to interval appendectomy, 24 underwent
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right colectomy, and 130 (0.9%) had the histopatho-
logical analysis demonstrating tumor [8, 11–16, 18]. The
incidence ranged from 0.3 to 3.2%. However, in patients
presenting with appendiceal inflammatory mass the rate
of neoplasm was much higher, from 10 to 29%, as stated
in Table 1. The incidence of tumor’s histological sub-
types is described in Table 2.
Interval appendectomy shows morbidity varying from
6 to 11% [8, 13, 14]. The most frequent complications
were assigned as minor representing wound infections,
but there were post-operative abscesses, colocutaneous
fistulas and hemorrhage [8]. Right-side hemicolectomy
was employed in 7 to 25% of the cases [8, 12], and there
was one fatal complication due to anastomotic leakage [8].
Review of the literature
Classifying and staging cecal appendix tumors
Recognizing the differences in the clinical presentation
and the prognosis of appendiceal primary tumors is es-
sential. When the tumor presents a signet-ring cell for-
mation, the average survival is 6 months. Meanwhile,
when histology shows a low-grade mucinous neoplasm,
the median overall survival increases to 8 years [17].
Recently, a study based in the database produced by
the Surveillance, Epidemiology and End Results (SEER)
of the National Institute of Cancer of Bethesda revealed
different survival rates for 5655 patients diagnosed with
a primary appendiceal tumor, depending on the hist-
ology. The same study also showed an increased number
of accidental diagnosis, which can be explained by a
boost in the number of patients submitted to computed
tomography and by the substantial use of laparoscopy,
improving the sight of the abdominal cavity [19] (Fig. 2).
The overall survival rate related to the disease in the
five coming years changed in line with the histologic
subtype [19] (Fig. 3; Table 3).
Fig. 1 Diagram of study selection
Table 1 Articles considering incidental neoplasm findings
among appendiceal abscess
Author Year Appendicitis (N) Abscess Neoplasm
N (%)
Carpenter S.G. et al. 2012 315 18 5 28
Lee W.S. et al. 2011 3744 (−) 28 (−)
Roberts J.K. et al. 2008 876 41 4 10
Wright G.P. et al. 2015 6038 82 11 12
Deelder J.D. et al. 2014 (−) 119 12 10
Lai H.W. et al. 2006 1873 70 7 10
Furman M.J. et al. 2013 376 17 5 29
Cerame M.A. et al. 1987 305 192 56 29
Tingstedt B. et al. 2002 93 30 3 10
Sum 13.244 569 131 23%
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The World Health Organization (WHO) classifies
appendiceal tumors in two main groups: appendiceal
carcinomas and neuroendocrine neoplasia (Table 4).
Appendiceal neuroendocrine (NET) tumors
Oberndorfer first described NET tumors in the ileum
and appendix in 1907, with mention to an indolent
course, although some of them, with a different pheno-
type, had a more unfavorable outcome [20]. The two
sub-groups of carcinoids based on their histological
characteristics are Enterochromaffin cell serotonin pro-
ducing carcinoid and its tubular variation with L-cell
glucagon-like peptide, and PP/PPY producing tumor.
Therefore, carcinoid is a definition mostly used for tu-
mors with more favorable histological characteristics
while neuroendocrine is a broader description, which in-
cludes more aggressive attributes of the disease.
Epidemiology and prognosis
NETs have approximately 0.15 per 100,000/year inci-
dence, according to the SEER registry. The frequency is
similar to other populations, based on European data-
bases [21–24].
Those NETs are frequent when considering only neu-
roendocrine gastroenteropancreatic tumors. There is
slight prevalence among women, affecting mostly
Caucasians, and its incidence could be underestimated,
since most of the cases, which are incidentally diag-
nosed, may not be notified in tertiary centers. The fre-
quency of appendectomies performed without any
particular reason is 3–9 per 1000 inhabitants [25, 26].
Appendiceal NET belongs to a sub-group of neoplasia
with a significant number of incidental diagnosis, repre-
senting about 80% of the neoplasia, including benign
and malignant tumors. The average age of the diagnosis
varies from 38 to 51 years old [27–29].
In most cases, the prognosis is excellent, with 100% of
overall 5-year survival rate for localized disease and 85–
100% for regional disease. Nevertheless, when including
staging, the 5-year survival rates vary between 70 and
85%. Advanced disease has unfavorable prognosis with a
5-year survival rate of 12 and 28%. Tumors with more
aggressive histology, such as Goblet cell carcinoids and
mixed adenoneuroendocrine carcinomas, were not in-
cluded in this study [27].
For NETs, Location, tumor depth, dimensions and
possible invasion of the mesoappendix are important
factors to calculate disease recurrence. In 70% of the
cases, the tumors are located at the tip of the appendix,
leading to a lower recurrence rate (Fig. 4). About its
length, tumors with 1 cm (60 to 80% of the cases), in-
vading through the subserosa or into the mesoappendix
for 3 mm also have a lower recurrence rate. However,
tumors with positive margins, located in the appendicu-
lar base, larger than 2 cm, or deeply invading the
mesoappendix, have a higher recurrence rate, suggesting
the need to perform additional resection [30–32].
The presentation of the disease is usually associated
with acute appendicitis. It rarely evolves into a metastatic
disease and hardly ever develops carcinoid syndrome.
Because there is no suspicion of NET before an ap-
pendectomy is performed, preoperative exams do not
offer additional information. Computed tomography or
Table 2 Incidence among histologic subtypes
Author Histologic subtypes % (N)
Carpenter S.G. et al. [11] LGMN 0%
Mucinous AdenoCa 20% (1)
In situ AdenoCa 20%(1)
Adenocarcinoma 40%(2)
Carcinoid 20%(1)
Lee W.S. et al. [12] LGMN 50%(14)
Mucinous AdenoCa 11%(3)
In situ AdenoCa 0%
Adenocarcinoma 7%(2)
Carcinoid 32%(9)
Wright G.P. et al. [8] LGMN
Mucinous AdenoCa 55%(6)
In situ AdenoCa 0%
Adenocarcinoma 9%(1)
Carcinoid 36%(4)
Lai H.W. et al. [13] LGMN 80%(5)
Mucinous AdenoCa 0%
In situ AdenoCa 0%
Adenocarcinoma 20%(2)
Carcinoid





Cerame M.A. et al. [15] LGMN 0%
Mucinous AdenoCa 40%(79)
In situ AdenoCa 1%(2)
Adenocarcinoma 59%(117)
Carcinoid
Tingstedt B. et al. [16] LGMN 33%(1)
Mucinous AdenoCa 0%
In situ AdenoCa 0%
Adenocarcinoma 66%(2)
Carcinoid 0%
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nuclear magnetic imaging could be used in postoperative
exams, to clinically stage the regional (lymph nodes) or
metastatic disease. Usually, colonoscopy will not reveal
the tumor, since in 70% of the time it occurs in the tip
of the appendix, rarely invading the caecum. Metabolic
studies, such as Octreo Scan and gallium 68 PET-CT,
are unusually performed. Laboratory tests, such as
serum chromogranin A and 5-hydroxyndoleaticeticacid,
are used selectively in the follow-up, or for suspicion
of possible carcinoid syndrome, respectively. A well--
differentiated NET, smaller than one centimeter and
treated with R0 resection, usually do not evolve into a
metastatic or regional disease in follow-up. Postopera-
tive computed tomography and MRI are justified when
tumors measure 1 to 2 cm. In cases of larger tumors,
deep invasion of the mesoappendix or angiolymphatic
invasion, image-led exams and metabolic tests, such as
OctreoScan and gallium 68 PET-CT, are often
required.
The histopathological test should be revised and must
describe location of the tumor, grade, mitotic index,
Ki-67 rate, dimension of the tumor, potential multifocal/
multicentric disease, vascular invasion, perineural inva-
sion, presence of non-endocrine component, presence
Fig. 2 The number of appendix tumors, adjusted by age, from 1997 to 2007, according to SEER database (per 100,000 inhabitants)
Fig. 3 Survival according to the histological type. Modified by Turaga et cols, Ann SurgOncol (2012) 19:1379–1385
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and number of lymph nodes, margin status, and TNM
system (Table 5).
Individual immunohistochemical studies could be in-
cluded to detect neuroendocrine markers, including chro-
mogranin A, synaptophysin, specific peptides and others.
Tumor grade is determined by the mitotic index and
Ki-67 (Table 6).th=tlb=
A major factor in the grading risk is the accurate sta-
ging of T in the TNM system since the diagnosis is usu-
ally incidental. For tumors T1a (UICC/AJCC), a simple
appendectomy is appropriate treatment, also in the
pediatric population. The overall survival in this group is
100% [33, 34].
Tumors larger than 2 cm (T2) are rare (<10%), but
carry a risk of becoming a metastatic disease in 25 to
40% of the cases. Because of such previous data, radical
resection is indicated, with follow-up for high-risk
disease [35–39].
Other criteria also considered is the location of the
tumor in the cecal appendix. Most of the tumors (60 to
75%) are located in the tip of the appendix, 5 to 20% in
the middle third and less than 10% in the appendiceal
base. It has been suggested metastasis frequently appear
in tumors located at the base, suggesting additional re-
section when the tumors have 1 to 2 cm length.
The decision to perform additional resection depends
on the extent of mesoappendix invasion, if present. Up
to 20% of the adults and 40% of the children undergo
further resection. It is possible that the invasion of the
mesoappendix be greater than initially reported. Despite
not being considered in the TNM staging, the invasion
of the mesoappendix could be related to a higher ap-
pearance of lymphatic invasion. When the malignancy
compromises more than 3 mm, there is increased risk of
nodal metastasis, and additional resection should be
considered [40, 41].
Surgical treatment
Resection options for NET are appendectomy, ileocolect-
omy, and right colectomy. For T1a tumors with no inva-
sion of the mesoappendix or not located in the
appendiceal base, an appendectomy should suffice.
When the tumor has invaded the mesoappendix in more
than 3 mm, or the tumor is located in the base, an ileo-
colectomy and right colectomy should be indicated.
However, there is not enough data to support the
Table 3 Specific survival rate of the disease in the coming five
years according to its histologic subtype
Histologic subtype. Survival rate per specific
disease in 5 years %.
Carcinoid tumor 91%
Globet cell carcinoid 81%.
Mucinous adenocarcinoma 58%
Non-specificadenocarcinoma 55%
Signet-ring cell formation. 27%
Table 4 The World Health Organization classification (2010)
Appendiceal carcinomas.
• Adenocarcinoma 8140/3
• Mucinous adenocarcinoma 8480/3
• Low-grade mucinous neoplasia 8480/1
• Signet-ring cell formation carcinoma 8490/3
• Undifferentiated carcinoma 8020/3
Neuroendocrine appendix neoplasias.
• Neuroendocrine tumors (NET).
• NET G1 (carcinoid) 8240/3
• NET G2 8249/3
• Neuroendocrine carcinomas (NEC) 8246/3
• NEC large cells type 8013/3
• NEC smal cells type 8041/3
• Mixed tumor:
• Mixed Adenoneuroendocrine carcinomas 8244/3
• Serotonin-producing endocrine carcinoma 8241/3
• Globet cell carcinoid 8243/3
• Tubular carcinoid 8245/1
• Peptide-producing/ Glucagon-producing large cell tumor PP/PYY
8152/1
Fig. 4 Well-differentiated neuroendocrine neoplasia, with 1 to 2 cm,
located in the tip of the appendix. Degree I (WHO) (Courtesy of
Andre Bouzas, MD – Oncology Institute - Santa Paula Hospital,
São Paulo
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hypothesis that an additional resection will increase pa-
tient survival and its morbidity should also be
considered.
When tumors have dimensions greater than 2 cm, the
ileocolectomy or right colectomy should be performed.
For those between 1 and 2 cm, other criteria are consid-
ered before performing additional resection, including
age, extension of mesoappendix invasion, and location.
However, there is scarce long-term follow-up informa-
tion of the patients. Angioinvasion or G2 could also be
taken into consideration when deciding for additional
resection. However, there is even less evidence published
about such criteria. Nevertheless, additional resection
has been used based on the consensus of the European
Neuroendocrine Tumor Society and when certain histo-
logic characteristics are present.
Carcinoid/Globet cell carcinoid
It is a mixed phenotype tumor, with goblet cell morph-
ology and neuroendocrine features more or less pro-
nounced. The incidence of such tumor is extremely rare,
representing less than 5% of primary appendiceal
tumors. The disease is common among Caucasians, who
represent 80% of the studied population [42].
The overall 5-year survival rate is lower than well-
differentiated NET and varies between 40% and 75%.
The disease can behave as adenocarcinomas with more
or less pronounced phenotype of goblet cells or neuro-
endocrine tumors [43]. In two-thirds of the goblet cell
tumor patients, the diagnosis is incidental, resulting
from an appendectomy for acute appendicitis, which
represents 50 to 60% of the initial presentation. Ten to
20% of them present peritonitis resulting from perfor-
ation [44, 45].
In 50% of the cases, the tumor invades the serosa
and the mesoappendix. In 15 to 30% of the patients,
there is the occurrence of distant metastasis, com-
monly in the ovaries, or in the lymph nodes. How-
ever, when measurement is possible, the progression
of the disease is increased when tumors have more
than 2 cm in length.
Other parameters foreseeing the aggressive behavior of
the illness include high mitotic counts (more than two
mitoses per 10 high-power fields); a Ki-67 greater than
3%; invasion into the serosa and into the mesoappendix;
angioinvasion; increased number of Paneth cells; en-
hanced production of mucin; production of pancreatic
polypeptide and lymph node involvement [46, 47].
In a retrospective series of 63 patients with carcinoid/
goblet cell carcinoid, Tang and collaborators demon-
strated the correlation between the pathological analysis
and the, aggressiveness of the disease. According to
the morphologic characteristics, three subgroups were
found [48]:
Group A –Typical Goblet cell carcinoid. Tumors had
minimum cellular atypia, rare mitoses and minimum
stromal invasion. The overall survival rate in 5 years
was 100%.
Group B – Goblet cell adenocarcinoid and signet-ring
cell formation. Tumors presenting an evident cellular
atypia, prominent desmoplasia and structural distortion
of the appendiceal wall. Overall survival rate in 5 years
was 36%.
Group C – Undifferentiated Adenocarcinoma with
goblet cell carcinoid. The overall survival rate in 5
years was 0%.
Table 5 TNM staging
Neuroendocrine tumors:
T:
Tx: Primary tumor which cannot be evaluated.
T0: No primary tumor was found in the appendix.
T1: Tumor with up to 2 cm dimension.
T1a: Up to one centimeter.
T1b: Up to 2 cm.
T2: Greater than two up to 4 cm or with extensions to the caecum.
T3: Greater than 4 cm or extension to the ileum.
T4: Tumor invades abdominal wall or adjacent organs or
perforated tumor
N:
NX: Nodal staging could not be evaluated for lack of information.
N0: Absence of metastasis in regional lymph nodes
N1: Presence of metasis in regional lymph nodes
M:
M0: Absence of distant metastasis
M1: Presence of distant metastasis
Stadium I: T1N0M0.
Stadium II: T2/T3N0M0.
Statium III: TN1M0 / T4N0M0.
Statium IV: TNM1.
Table 6 Grade of NET tumors according to the World Health
Organization (WHO), considering the Mitotic index and Ki-67
Grade NETs appendix Tumor
differentiation
Low grade (G1) <2 mitoses /10 high power




2–10 mitoses / 10 HPF or
Ki-67 between 3 and 20%.
Well-differentiated
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Epithelial tumors of the appendix
Merling published the first reference to appendiceal neo-
plasms in 1838. In 1903, Elting published a series of pa-
tients with tumors emerging from preexisting adenomas
in the appendix, assuming a growth pattern with cystic
dilatation of the appendix (mucinous tumors). He real-
ized that sometimes it could exhibit a growth pattern
similar to primary colon tumors (colonic-types), these
are either polypoid or ulcerative, emerging from tubular
or tubulovillous adenomas [49].
The mucinous-type is inclined to rupture and mucin
extravasation, with or without mucin epithelia into
the abdominal cavity, resulting into Pseudo myxoma
Peritonei [42, 50]. The Colonic-type is similar to
colon adenocarcinomas and results in lower overall
survival rate than mucinous-type tumors [51].
In an analysis based on the SEER registry between
1973 and 2004, 2791 patients with malignant appendi-
ceal neoplasm were studied. Adenocarcinomas were
more frequent, responding for 65.4% of the cases. While
neuroendocrine tumors have presented a regular occur-
rence in the same period, there was a 260% increase in
carcinoma rates. The overall 5-year survival rate for
those patients was 46.5%. When considering mucinous
cystadenocarcinoma, it rose to 59% in all stages, and in
signet-ring cell formation tumors, to 20.3% [52].
Mucinous appendiceal tumors
Although appendiceal mucinous tumors are recognized
as benign, as per their histology, those tumors can pro-
gress to peritoneal dissemination.
Ronnet and collaborators, in 1995, published a classifi-
cation based on 109 patients who presented peritoneal
dissemination caused by mucinous epithelial tumor in
appendix [53].
– Disseminated Peritoneal Adenomucinosis (DPAM):
Peritoneal lesions composed of abundant
extracellular mucin, with minimum cytologic
atypia and rare mitoses. In all the cases, the
appendix tumor was an adenoma
– Peritoneal Mucinous Carcinomatosis (PMCA):
Peritoneal lesions composed of more abundant
mucinous epithelium with the architectural and
cytologic features of carcinoma. The primary tumor
was mucinous appendix carcinoma, with prominent
cytologic atypia and, in some cases, with signet-ring
cell formation. The distinct subgroup can potentially
evolve to metastatic disease to other organs or
lymph nodes.
In 2003, Misdraji and collaborators reclassified mucin-
ous disease to low-grade mucinous neoplasia (LGMN)
and mucinous adenocarcinoma (Figs. 5 and 6) [10].
Clinical presentation and prognosis
Performance and patient prognosis vary, and the diagno-
sis can be incidental, in a case of complicated acute ap-
pendicitis. However, preoperative diagnosis can be made
by abdominal ultrasound with the finding of an appendix
mucocele, indicating a dilated appendix filled with mu-
cinous content (Figs. 7 and 8).
Eventually, in a similar clinical scenario, there is a con-
dition in which the disease is located and restricted to
the right lower quadrant of the abdomen. In those cases,
mucin deposits can be found in the serosa, in the
mesoappendix or extending to right iliac fossa. Those
mucin lakes do not contain any neoplastic cells when
submitted to pathological analysis [54].
Fig. 5 Low-grade mucinous neoplasia (LAMN – Grade 1 WHO),
measuring 2 cm, invading the distal third with free margin
Fig. 6 Surgical specimen from ileocolectomy to treat perforated
appendiceal mucinous adenocarcinoma
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Yantiss and collaborators have studied the prognosis of
patients with appendiceal mucinous neoplasms and
mucin deposits in the right lower quadrant. Of 65 pa-
tients, 77% did not present cells in the mucin lakes while
23% had low-grade mucin epithelial cells. In follow-up
after 52 months, 96% of the patients without cells in the
mucin lakes were free the disease. In that group of
patients showing no extra-appendicular mucinous epi-
thelium, two of them developed peritoneal dissemin-
ation, but the appendix of those two individuals was not
analyzed in the study [55]. Regarding patients presenting
extra-appendicular mucinous epithelium, 33% evolved
to pseudomyxoma peritonei. The study demonstrated
excellent prognosis for patients with mucin dissemination
in the right lower quadrant and no extra-appendicular
mucinous epithelium [55] (Figs. 9 and 10).
Pseudomyxoma peritonei is considered by the UICC/
AJCC and the WHO a malignant disease secondary to a
carcinoma [56, 57].
The extension of a disease with extra-appendicular mu-
cinous epithelium significantly affects patient prognosis.
In a series of 184 patients, Carr and collaborators ob-
served that mucinous disease restricted to the appendix
has an indolent course. When the neoplasia is limited to
the muscular mucosa, which is intact, it is called adenoma.
When there is invasion of deeper layers or extra-
appendicular extension, it is called carcinoma. Tumors
that do not invade the muscular mucosa, but develop
mucin deposits in the serosa without cells, are referred as
uncertain potential for malignity [58].
Tumors characterized by neoplastic mucinous epithe-
lium invading the muscular mucosa should be consid-
ered as high risk of peritoneum dissemination and
classified and staged according to WHO and AJCC. Mu-
cinous tumors with extra-appendicular dissemination of
mucinous epithelium are considered by WHO low or
high-grade mucinous adenocarcinoma, depending on
the cytoarchitecture atypia.
Miner and collaborators analyzed histologic character-
istics of appendiceal mucinous tumors presenting with
peritoneal dissemination treated with surgical cytoreduc-
tion. In a retrospective series of 97 patients, complete
cytoreduction was possible in 53% of the patients. Low--
grade cytology was independently associated with longer
disease-free survival. Some 90% of patients who lived an
Fig. 7 Dilated appendix, with a diameter of 3.5 cm compatible with
appendiceal mucocele, in ultrasound
Fig. 8 Axial computerized tomography view of a burst cecal
appendix (up to 3.5 cm), with thin and regular walls, and no signs of
densification of adjacent adipose tissue. This corresponds to the
cystic formation already described in the ultrasound, compatible
with mucocele of undetermined etiology. Appendectomy revealed
well-differentiated mucinous adenocarcinoma, with invasion into of
the muscularis mucosae
Fig. 9 Axial computerized tomography view showing mucin lakes in a
patient with low-grade appendiceal mucin adenocarcinoma limited to
the right iliac fossa. Pathological analysis revealed extra-appendicular
mucin without the presence of mucinous epithelium
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additional 10 years were diagnosed with low-grade tu-
mors [59].
Traditional treatment for pseudo myxoma peritonei is
composed of surgical cytoreduction associated with hyper-
thermic intraperitoneal chemotherapy (HIPEC) [60].
A retrospective analysis based on 2289 patients diag-
nosed with pseudo myxoma peritonei resulting from
perforated appendiceal mucinous tumors showed the
importance of associating complete macroscopic cytore-
duction and HIPEC. The study reported 10 and 15 years
survival in 63 and 59% of the cases respectively, with
perioperative mortality of 2% [61].
Appendiceal adenocarcinoma – Colonic-type
There are few studies on Colonic-type appendiceal
adenocarcinoma. In a recent German multi-centric study
about primary appendiceal carcinomas, 99 patients, with
an average age of 64 years old, were identified. Those tu-
mors had an average length of 3.27 cm, 72% were T3/T4
tumors, and 36.4% of them had lymph node metastasis.
More than 60% were moderately differentiated, and
more than 20% were poorly differentiated. Stage IV dis-
ease represented 23.2% of the cases, and overall survival
was 47.5% for all stages. When compared to other more
frequent primary appendiceal tumors (carcinoid and
mucinous adenocarcinoma), the colonic-type has the
higher incidence of lymph nodes metastasis [62, 63].
Such information reinforces the indication of any sur-
gical intervention (appendectomy/ileocolectomy) re-
quired to treat and appendiceal inflammatory mass after
conservative treatment (Figs. 11 and 12).
Literature is scarce when discussing patients diagnosed
with adenocarcinomas with signet-ring cell formation or
undifferentiated. The effects of therapeutic interventions
(cytoreduction and systemic chemotherapy) in this
group are unknown. In a series analyzing 142 patients
diagnosed with undifferentiated tumors or with signet-
ring cell formation (defined by the WHO as more than
50% of the cells in the tumor in a signet-ring formation),
the average age was 52 years old, and 75% presented
metastatic disease. In patients with metastatic disease,
all of them had peritoneum involvement, and 36% also
had it in the ovaries. The median survival rate was
2 years for patients diagnosed with undifferentiated
adenocarcinomas and 2.5 years for those with adenocar-
cinomas with signet-ring cell formation. Patients who
were submitted to surgical cytoreduction had a median
recurrence-free survival of 1.2 years, and an overall
Fig. 11 PET-CT of a patient subjected to appendectomy to treat acute appendicitis with incidental diagnosis of appendiceal tubular adenocarcinoma
with signet-ring cell formation T3NXMX. In postoperative follow-up, CEA was elevated and the PEC-CT revealed pericecal lymphadenopathy
Fig. 10 Intraoperative view of pericecal and retrocecal mucin. The
disease was limited to the right iliac fossa. Pathological analysis
analysis revealed no cells in the mucin
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survival of 4.2 years was achieved when patients under-
went a complete cytoreduction. This surgical approach
is also improves overall survival of patients with A oligo-
metastatic peritoneal disease. Unfortunately, complete
cytoreduction was only achieved in 21% of the patients [64].
Conclusion
Hidden appendiceal neoplasm findings in post-operative
appendectomy for acute appendicitis is a rare event,
fortunately. However, its incidence in acute appendiceal
inflammatory mass is not negligible. In our point of view
all patients submitted upfront to a more conservative
treatment (percutaneous drainage and antibiotics) should
be submitted to interval appendectomy.
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